You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

~ Buy the ROCKLATAN (latanoprost; netarsudil dimesylate) Drug Profile, 2024 PDF Report in the Report Store ~

ROCKLATAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Rocklatan, and when can generic versions of Rocklatan launch?

Rocklatan is a drug marketed by Alcon Labs Inc and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in fourteen countries.

The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.

DrugPatentWatch® Generic Entry Outlook for Rocklatan

Rocklatan was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ROCKLATAN?
  • What are the global sales for ROCKLATAN?
  • What is Average Wholesale Price for ROCKLATAN?
Drug patent expirations by year for ROCKLATAN
Drug Prices for ROCKLATAN

See drug prices for ROCKLATAN

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ROCKLATAN
Generic Entry Date for ROCKLATAN*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ROCKLATAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Aerie PharmaceuticalsPhase 4

See all ROCKLATAN clinical trials

Pharmacology for ROCKLATAN
Paragraph IV (Patent) Challenges for ROCKLATAN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ROCKLATAN Ophthalmic Solution latanoprost; netarsudil dimesylate 0.005%/0.02% 208259 2 2021-12-20

US Patents and Regulatory Information for ROCKLATAN

ROCKLATAN is protected by sixteen US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ROCKLATAN is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting ROCKLATAN

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Combination therapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Compositions for treating glaucoma or reducing intraocular pressure
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Combination therapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Dual mechanism inhibitors for the treatment of disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Combination therapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Combination therapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Combination therapy
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Alcon Labs Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for ROCKLATAN

When does loss-of-exclusivity occur for ROCKLATAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 14228790
Patent: Combination therapy
Estimated Expiration: ⤷  Sign Up

Patent: 18202965
Patent: Combination therapy
Estimated Expiration: ⤷  Sign Up

Patent: 18202990
Patent: Combination therapy
Estimated Expiration: ⤷  Sign Up

Patent: 20203976
Patent: COMBINATION THERAPY
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 05089
Patent: COMPOSE D'ISOQUINOLINE POUR TRAITER DES MALADIES OCULAIRES (ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF OCULAR DISEASES)
Estimated Expiration: ⤷  Sign Up

China

Patent: 5263494
Patent: Combination therapy
Estimated Expiration: ⤷  Sign Up

Patent: 9528721
Patent: 联合治疗 (Combination therapy)
Estimated Expiration: ⤷  Sign Up

Patent: 0396085
Patent: 联合治疗 (Combination therapy)
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 11943
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 76080
Patent: CONJUGÉS DE COMPOSÉS ISOQUINOLINE ET DE PROSTAGLANDINES (CONJUGATES OF ISOQUINOLINE COMPOUNDS AND PROSTAGLANDINS)
Estimated Expiration: ⤷  Sign Up

Patent: 61484
Patent: TRAITEMENT COMBINÉ (COMBINATION THERAPY)
Estimated Expiration: ⤷  Sign Up

Patent: 11943
Patent: COMPOSÉ POUR L'UTILISATION DANS LE TRAITEMENT DES MALADIES OCULAIRES (COMPOUND FOR USE IN THE TREATMENT OF OCULAR DISORDERS)
Estimated Expiration: ⤷  Sign Up

Patent: 18759
Patent: TRAITMENT COMBINÉ (COMBINATION THERAPY)
Estimated Expiration: ⤷  Sign Up

Finland

Patent: 11943
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 61618
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 16515520
Patent: 併用療法
Estimated Expiration: ⤷  Sign Up

Patent: 19094339
Patent: 併用療法 (COMBINATORY TREATMENT)
Estimated Expiration: ⤷  Sign Up

Patent: 20125355
Patent: 併用療法 (COMBINATION THERAPY)
Estimated Expiration: ⤷  Sign Up

Patent: 20143163
Patent: 併用療法 (COMBINATION THERAPY)
Estimated Expiration: ⤷  Sign Up

Patent: 21046439
Patent: 併用療法 (COMBINATION THERAPY)
Estimated Expiration: ⤷  Sign Up

Patent: 23030072
Patent: 併用療法
Estimated Expiration: ⤷  Sign Up

Netherlands

Patent: 1101
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 11943
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 11943
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 76199
Estimated Expiration: ⤷  Sign Up

Patent: 52377
Estimated Expiration: ⤷  Sign Up

Patent: 42898
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ROCKLATAN around the world.

Country Patent Number Title Estimated Expiration
Australia 2017248440 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE ⤷  Sign Up
Spain 2553827 ⤷  Sign Up
Canada 2905089 COMPOSE D'ISOQUINOLINE POUR TRAITER DES MALADIES OCULAIRES (ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF OCULAR DISEASES) ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2010126626 ⤷  Sign Up
Canada 2760562 INHIBITEURS A MECANISME DOUBLE POUR LE TRAITEMENT DE MALADIE (DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE) ⤷  Sign Up
Japan 2012525386 ⤷  Sign Up
Finland 3811943 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ROCKLATAN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3053913 132020000000043 Italy ⤷  Sign Up PRODUCT NAME: NETARSUDIL(RHOKIINSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1400, 20191121
3461484 132021000000068 Italy ⤷  Sign Up PRODUCT NAME: COMBINAZIONE DI LATANOPROST E NETARSUDIL(ROCLANDA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1502, 20210108
3053913 20C1017 France ⤷  Sign Up PRODUCT NAME: NETARSUDIL, OU ENANTIOMERE, DIASTEREOMERE, SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1400 20191121
3461484 2021C/515 Belgium ⤷  Sign Up PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108
3053913 2020/016 Ireland ⤷  Sign Up PRODUCT NAME: NETARSUDIL, OR AN ENANTIOMER, DIASTEREOMER, SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/19/1400 20191121
0364417 97C0128 France ⤷  Sign Up PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
3053913 122020000016 Germany ⤷  Sign Up PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.